Program: Oral and Poster Abstracts
Monday, December 12, 2011: 2:45 PM-4:15 PM
Douglas Pavilion B (Manchester Grand Hyatt San Diego)
William A Wood, MD, MPH, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine and Leslie E. Lehmann, MD, Dana-Farber Cancer Institute
No relevant conflicts of interest to declare.
Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)
See more of: Oral and Poster Abstracts
*signifies non-member of ASH